We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sarepta & BioMarin Settle Patent Litigation on Exon Skipping
Read MoreHide Full Article
Sarepta Therapeutics, Inc. (SRPT - Free Report) and BioMarin Pharmaceutical Inc. (BMRN - Free Report) , have settled their ongoing global patent litigation regarding the exclusive license on a patent pertaining to exon skipping technology used in Duchenne muscular dystrophy (DMD) therapies. BioMarin has licensed the global exclusive rights to its DMD patent estate for Exondys 51 and all future exon-skipping products to Sarepta Therapeutics.
Exondys 51 is a key drug for Sarepta and is marketed for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.
A look at the company’s share price movement shows that, Sarepta has outperformed the Zacks categorized Medical-Biomed/Genetics industry so far this year. While the stock has rallied 23.5%, the broader industry witnessed a gain of 8.8%.
Per the agreement, Sarepta will make a one-time payment of $35 million to Biomarin plus unspecified regulatory and commercial milestone payments for exons 51, 45, 53, and on future exon-skipping products. Additionally, the company will pay BioMarin royalties for compounds skipping exons 51, 45, and 53, and possibly on future exon-skipping products.
BioMarin is entitled to receive 5% royalty on U.S. sales (through 2023) of Exondys 51 and both exons 45 and 53 skipping compounds, which use the exon skipping technology, and 8% royalty on European sales of the products (through Sep 2024).
BioMarin, however, has held back the right to convert the license to a co-exclusive right in case it decides to proceed with an exon-skipping therapy for DMD.
If Sarepta had not made the settlement with BioMarin, the latter could preclude Sarepta from commercializing Exondys 51 in several jurisdictions. Thus the settlement of patent litigation and the global license from Biomarin removes a major overhang for Sarepta.
Sarepta currently carries a Zacks Rank #3 (Hold). Better-ranked health care stocks in the same space include Enzo Biochem, Inc. (ENZ - Free Report) and Sanofi (SNY - Free Report) . While Enzo Biochem sports a Zacks Rank #1 (Strong Buy), Sanofi holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 64.8% year to date.
Sanofi’s earnings per share estimates increased from $3.08 to $3.18 for 2017 and from $3.26 to $3.30 for 2018, over last 60 days. The company pulled off positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 18% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Sarepta & BioMarin Settle Patent Litigation on Exon Skipping
Sarepta Therapeutics, Inc. (SRPT - Free Report) and BioMarin Pharmaceutical Inc. (BMRN - Free Report) , have settled their ongoing global patent litigation regarding the exclusive license on a patent pertaining to exon skipping technology used in Duchenne muscular dystrophy (DMD) therapies. BioMarin has licensed the global exclusive rights to its DMD patent estate for Exondys 51 and all future exon-skipping products to Sarepta Therapeutics.
Exondys 51 is a key drug for Sarepta and is marketed for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.
A look at the company’s share price movement shows that, Sarepta has outperformed the Zacks categorized Medical-Biomed/Genetics industry so far this year. While the stock has rallied 23.5%, the broader industry witnessed a gain of 8.8%.
Per the agreement, Sarepta will make a one-time payment of $35 million to Biomarin plus unspecified regulatory and commercial milestone payments for exons 51, 45, 53, and on future exon-skipping products. Additionally, the company will pay BioMarin royalties for compounds skipping exons 51, 45, and 53, and possibly on future exon-skipping products.
BioMarin is entitled to receive 5% royalty on U.S. sales (through 2023) of Exondys 51 and both exons 45 and 53 skipping compounds, which use the exon skipping technology, and 8% royalty on European sales of the products (through Sep 2024).
BioMarin, however, has held back the right to convert the license to a co-exclusive right in case it decides to proceed with an exon-skipping therapy for DMD.
If Sarepta had not made the settlement with BioMarin, the latter could preclude Sarepta from commercializing Exondys 51 in several jurisdictions. Thus the settlement of patent litigation and the global license from Biomarin removes a major overhang for Sarepta.
Sarepta Therapeutics, Inc. Price and Consensus
Sarepta Therapeutics, Inc. Price and Consensus | Sarepta Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Sarepta currently carries a Zacks Rank #3 (Hold). Better-ranked health care stocks in the same space include Enzo Biochem, Inc. (ENZ - Free Report) and Sanofi (SNY - Free Report) . While Enzo Biochem sports a Zacks Rank #1 (Strong Buy), Sanofi holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 64.8% year to date.
Sanofi’s earnings per share estimates increased from $3.08 to $3.18 for 2017 and from $3.26 to $3.30 for 2018, over last 60 days. The company pulled off positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 18% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>